Reached Swiss firm Roche Pharmaceuticals for an effective way enables drugs used antibodies from reaching the brain and impenetrable, which opens the door of hope to reach effective treatments for diseases such as Alzheimer's.
Experiments were carried out on the technology shuttle brain developed in mice only, which allows skipping blood-brain barrier which separates the blood and fluid extracellular brain in the central nervous system, which was an obstacle in the research of medicines for nerves, because this barrier was closing the door in the face of large molecules such as antibodies and prevents it from reaching the brain.
Alzheimer's disease is a fatal disease that eliminates jobs brain and infected 44 million people worldwide and expects the International Association for the fight against Alzheimer's, the number of people infected will increase three-fold by 2050. , and although it does not yet exist treat the disease effectively or medication to slow him down being a number of companies including Roche and Eli Lilly and Merck & Ku and Johnson & Johnson research to get to the origin of the disease.
For over 15 years the failure of more than one hundred experimental drug for Alzheimer's in the testing stages. But industry analysts believe that the return will be rewarding in the case of a real cure for the disease and estimated market sales of about ten billion dollars a year, and operating technology developed for Roche kidnapping transfer mechanism naturally used by the human body naturally to transport proteins within the brain.
Rare diseases at Roche during a telephone conversation, "designed in the foundation of this vehicle, which is called the shuttle, which fuse with the transport mechanism of this and the movement of cargo to the brain." and concluded that the results of the study, published Wednesday in the journal (Neuron) that this technology has helped to increase the concentration of antibodies in the brains of mice and it reduced the size of the plates starchy, which is a sure sign of Alzheimer's disease.
Experiments were carried out on the technology shuttle brain developed in mice only, which allows skipping blood-brain barrier which separates the blood and fluid extracellular brain in the central nervous system, which was an obstacle in the research of medicines for nerves, because this barrier was closing the door in the face of large molecules such as antibodies and prevents it from reaching the brain.
Alzheimer's disease is a fatal disease that eliminates jobs brain and infected 44 million people worldwide and expects the International Association for the fight against Alzheimer's, the number of people infected will increase three-fold by 2050. , and although it does not yet exist treat the disease effectively or medication to slow him down being a number of companies including Roche and Eli Lilly and Merck & Ku and Johnson & Johnson research to get to the origin of the disease.
For over 15 years the failure of more than one hundred experimental drug for Alzheimer's in the testing stages. But industry analysts believe that the return will be rewarding in the case of a real cure for the disease and estimated market sales of about ten billion dollars a year, and operating technology developed for Roche kidnapping transfer mechanism naturally used by the human body naturally to transport proteins within the brain.
Rare diseases at Roche during a telephone conversation, "designed in the foundation of this vehicle, which is called the shuttle, which fuse with the transport mechanism of this and the movement of cargo to the brain." and concluded that the results of the study, published Wednesday in the journal (Neuron) that this technology has helped to increase the concentration of antibodies in the brains of mice and it reduced the size of the plates starchy, which is a sure sign of Alzheimer's disease.
RSS Feed